Andrew Berens
Stock Analyst at Leerink Partners
(2.38)
# 2,422
Out of 5,182 analysts
98
Total ratings
47.56%
Success rate
-0.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Outperform | $52 → $58 | $23.89 | +142.78% | 11 | Mar 3, 2026 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $5.22 | +187.36% | 1 | Oct 31, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $34.74 | -42.43% | 6 | Jan 5, 2023 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $8 | $7.32 | +9.29% | 1 | Jan 23, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $27.79 | +43.94% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $105.28 | +41.53% | 3 | Nov 17, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $7.66 | +226.37% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $131.06 | -54.22% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $10.11 | -10.98% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $1.83 | +227.87% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $880 → $762 | $714.89 | +6.59% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.91 | +743.99% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $131.33 | -26.90% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $98.56 | -20.86% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $16.52 | +69.49% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $182.85 | -56.80% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $4.41 | +512.24% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $14.55 | +71.82% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $8.40 | +376.19% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.95 | +2,171.19% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $19.39 | +3.15% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $23.02 | +8.60% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $9.65 | -17.10% | 7 | Jul 14, 2017 |
Zymeworks
Mar 3, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $23.89
Upside: +142.78%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $5.22
Upside: +187.36%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $34.74
Upside: -42.43%
Relmada Therapeutics
Jan 23, 2026
Upgrades: Outperform
Price Target: $8
Current: $7.32
Upside: +9.29%
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $27.79
Upside: +43.94%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $105.28
Upside: +41.53%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $7.66
Upside: +226.37%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $131.06
Upside: -54.22%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $10.11
Upside: -10.98%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $1.83
Upside: +227.87%
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $714.89
Upside: +6.59%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $3.91
Upside: +743.99%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $131.33
Upside: -26.90%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $98.56
Upside: -20.86%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $16.52
Upside: +69.49%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $182.85
Upside: -56.80%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $4.41
Upside: +512.24%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $14.55
Upside: +71.82%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $8.40
Upside: +376.19%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.95
Upside: +2,171.19%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $19.39
Upside: +3.15%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $23.02
Upside: +8.60%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $9.65
Upside: -17.10%